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Abstract: Cell therapy has the potential to regenerate cardiac tissue and treat a variety of cardiac
diseases which are currently without effective treatment. This novel approach to treatment has
demonstrated clinical efficiency, despite low retention of the cell products in the heart. It has been
shown that improving retention often leads to improved functional outcome. A feasible method
of improving cell graft retention is administration of injectable hydrogels. Over the last decade,
a variety of injectable hydrogels have been investigated preclinically for their potential to improve
the effects of cardiac cell therapy. These hydrogels are created with different polymers, properties,
and additional functional motifs and differ in their approaches for encapsulating different cell types.
Only one combinational therapy has been tested in a clinical randomized controlled trial. In this
review, the latest research on the potential of injectable hydrogels for delivery of cell therapy is
discussed, together with potential roadblocks for clinical translation and recommendations for future
explorations to facilitate future translation.
Keywords: hydrogel; cell therapy; regenerative therapy; cardiac disease; heart failure; mesenchymal
stem cell; delivery
1. Introduction
Cardiovascular diseases remain the leading cause of death worldwide and include
pathological disorders such as acute myocardial infarction (AMI) and heart failure [1].
Current treatment options focus primarily on slowing disease progression and ameliorating
symptoms, but therapies that regenerate or reverse myocardial remodeling have yet to be
developed and/or implemented in clinical practice [2]. Therefore, several patients with
end-stage heart failure will develop a need for heart transplantation, a treatment highly
restricted by donor availability.
For almost two decades, cell therapy has been investigated for treatment of several
cardiovascular diseases. Various cell types have been tested in clinical trials, and many
types have been investigated in preclinical studies. Several cell types have been demon-
strated to have a good clinical safety profile and to be capable of ameliorating or reversing
the myocardial remodeling [2]. Cell therapy may very well be groundbreaking in treatment
of otherwise non-treatable conditions, including several heart diseases.
Though the new cell therapy has promising perspectives, it has limits. Already
in 2011, Malliaras and Marban acknowledged that the low retention in the heart was
a hindrance for the effectiveness of cardiac cell therapy [3]. In the same paper published
a decade ago, the authors mention that studies using different regenerative cell types found
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a good correlation between cardiac retention rates and efficiency of the treatment and
concluded that improving physical retention may hold the key to unlocking the potential
of cell therapy for cardiological diseases. The following year, Mathieu et al. found an
improvement of cardiac cell therapy by administering the cells in an injectable hydrogel [4].
During the last decade, several approaches for improving the retention of cell ther-
apy in the heart have been tested. Some of the cell loss is explained by migration via
the lymphatic system [5]. This could be improved by tuning the cell products by overex-
pressing adhesion and integration of surface proteins. However, even if the cell product
is more prone to adhere and integrate in the environment, the physical pressure from
the contracting heart, as well as the hostile inflammatory environment, will still lead to
expulsion and immune system activation [6,7]. This calls for a technology providing better
retention in the tissue as well as shielding of the cell product. Since cell therapy products
need to interact with the endogenous cell populations, a certain degree of porosity is
essential in addition to the retention and shielding. All of this is a perfect fit for hydrogels.
Since the publication by Malliaras and Marban, the many attempts to enhance cardiac cell
therapy using biomaterials, including hydrogels, have resulted in hundreds of preclinical
studies and the first clinical randomized controlled trial being published in 2020 [6,8].
This review describes the potential functional benefit of using injectable hydrogels for
cell therapy administration. Furthermore, the different cell and hydrogel types as well as
roadblocks for clinical translation are elucidated. Due to our focus on large-scale clinical
application, non-injectable scaffolds or cardiac patches are not within the scope of this
review.
2. Injectable Hydrogels
In simple terms, hydrogels are highly hydrated biomaterials that enable 3D encap-
sulation of living cells. The high water content enables an efficient exchange of nutrients
and metabolic waste products with the surrounding environment, while providing the en-
capsulated cells with a hydrated 3D and immune protective environment. Hydrogels can
also be fine-tuned to yield mechanical properties similar to the extracellular matrix (ECM)
of native tissues and provide cells with native-like biochemical stimuli that can direct
them towards desired fates. Importantly, the soft nature of hydrogels makes them ideal
candidates for injectable biomaterials capable of carrying cells into pre-destined target sites
inside the human body [9]. The fact that these injectable cell carriers can offer protection
against the potential compromising mechanical shear forces during the injection phase
while providing the injected cells with a well-controlled and retained 3D microenvironment
makes them feasible for cardiac cell delivery as well.
2.1. Natural Hydrogels
Hydrogels are often divided into natural or synthetic hydrogels. Each group has their
own advantages and challenges. Several natural biopolymers have already been approved
for clinical application, making the use of these gels a quick choice for translatable cell
carriers. Natural hydrogels include collagen, silk fibroin, chitosan, cellulose, alginate,
gelatin, and hyaluronate hydrogels [10–17]. The natural polymers are known to be very
biocompatible. Most natural hydrogels, including those created from hyaluronate, fibrin,
and collagen, are degraded by cellular enzymes, while alginate hydrogels degrade by ion
exchange with the surrounding environment. For these reasons, the cross-linking and
degradation of unmodified natural hydrogels is considered uncontrollable in vivo but
very safe unless the gels are modified [18]. Since some of the natural polymers either are
biologically inert or incapable of encompassing the electrical and mechanical properties of
the target tissue, ECM engineers have, over the years, developed several methodologies
to remedy such shortcomings. A widely used strategy for enhancing the bioactivity of
biologically inert hydrogels is through growth factor or arginine–glycine–aspartic acid
peptide (RGD) conjugation on the hydrogel backbone [19].
Gels 2021, 7, 7 3 of 22
2.2. Synthetic Hydrogels
In contrast to natural hydrogels, synthetic hydrogels are highly controllable and
customizable. The use of synthetic hydrogels for cell delivery has increased during re-
cent years. The number of synthetic hydrogel pre-polymers used in tissue engineering is
quite impressive and rapidly growing. They include various polypeptides and biopoly-
mers expressed by genetically altered cells and bacteria or others such as polyvinyl alco-
hol (PVA), polyacrylamide, poly(N-isopropylacrylamide) (PNIPAm), polyethylene glycol
(PEG), and poly(3,4-ethylenedioxythiophen) polystyrene sulfonate (PEDOT:PSS) made by
chemists [20]. Synthetic hydrogels are not considered to be as biocompatible as natural
polymers, either due to their origin of synthesis or their cross-linking [9,18]. Many of
the synthetic hydrogels are not degraded in vivo unless modified by, i.e., incorporation
of natural biodegradable polymers. To circumvent this issue, self-assembling peptide
hydrogels such as the RADA hydrogel have been shown to degrade without toxicity of
degradation products [21]. From a clinical perspective, only PEG and PVA have, so far,
managed to maintain a good reputation among physicians and federal agencies [22].
The choice of hydrogel type for cell delivery should be made carefully, as hydrogel
properties affect the incorporated cells. Consequently, the choice should not be guided
by preference but rather by impact on the cells used for the treatment and the tissue
environment and administration options in the clinical indication.
3. Hydrogel Properties and Delivery Depends on Clinical Indication
3.1. Acute Myocardial Infarction
So far, cell therapy has been shown to have little effect in patients with acute myocar-
dial infarction (AMI), despite a body of preclinical evidence showing the opposite [23,24].
This has most recently been shown in the Phase III autologous bone marrow cell therapy
in acute myocardial infarction trial (BAMI) [25]. The investigators concluded that the im-
provement in the standard of care for AMI patients is simply so good that it requires too
many patients, close to 10,000, to demonstrate a potential effect of cell therapy on hard
end-points such as death. As an important note, this trial did not meet the number of
recruited patients and ended up including 375 out of the planned 3000 [25]. Since this
is caused by the control group, the results will most likely be the same across all cell
therapies for AMI. As such, if cell therapy is to be effective in AMI, the current clinical ap-
proach needs to be significantly improved. A feasible method of doing this while retaining
the workflow optimized over the last 10 years of cell therapy would be administration of
the cells in injectable hydrogels.
If researchers plan to apply hydrogels for cell delivery in AMI, it is important to be
aware of the myocardial environment following AMI. The extensive inflammation and
apoptosis after AMI result in the peri-infarct myocardium being relatively soft [26]. This
makes it difficult to inject cells by transendocardial stem cell injection (TESI), though
this administration has been shown to be superior in terms of cell retention and clinical
efficacy [6,27–29]. TESI is performed using a catheter to enter the left ventricle through
the venous system. The conductivity of the ventricle can be mapped using the NOGA
mapping system, creating a map of the non-conductive infarct area. Clinicians look at
the X-ray for TESI injection and are able to map the injection site in the NOGA program.
As such, it is possible to deliver cells to the peri-infarct area through minimally invasive
methods. However, due to the soft myocardium and ease of access, most cell therapies
in AMI have been delivered by intracoronary injection [23]. If this approach is to be
continued, the chosen hydrogel for delivery must be able to cross the endothelial barrier
and crosslink at the site of injury. Such hydrogels have been developed and applied, taking
advantage of AMI-specific tissue attributes such as increased calcium levels [30].
3.2. Chronic Ischemic Heart Failure and Non-Ischemic Dilated Cardiomyopathy
In contrast to AMI, cell therapy has been shown to be clinically effective in treatment
of chronic ischemic heart failure (CIHF) [23,31]. The myocardium of heart failure patients
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is not as soft as in AMI patients, making it more feasible to use TESI delivery. Though there
is persistent chronic inflammation in CIHF, it is not to the same scale and with as dynamic
changes as in AMI [32]. This requires less shielding against the hostile environment caused
by the disease, though there will still be an acute immune reaction to the intramuscular
injection in itself.
In addition to CIHF, cell therapy shows promising tendencies in non-ischemic di-
lated cardiomyopathy (NIDCM), with even larger effect size and solid preclinical evi-
dence [33,34]. NIDCM is a disease with varying etiology, including genetic mutations,
exposure to certain drugs and toxins, and autoimmune diseases. Despite this variation,
common tissue denominators are present in the myocardium, in which the myocardial
microenvironment is characterized by fibrosis, chronic inflammation, oxidative stress,
and dysfunctional vessels [28]. Consequently, survival and engraftment of transplanted
cells might be optimized by shielding the cells from the harsh microenvironment, thus im-
proving the treatment effect. However, there are currently no studies on hydrogel-delivered
cell therapy in NIDCM [34].
As with CIHF, the cardiac tissue in NIDCM is less soft and porous, making TESI
injections feasible. As TESI is currently applied in several clinical trials with cell therapy,
designing a hydrogel for this purpose may ease the translation into the clinic [28,35,36].
Though TESI has proven to be the best current option for cell delivery, it poses a challenge
for cell delivery in hydrogels. A common use of hydrogel for cell delivery is to apply it
as an injection medium for the cells—this will be referred to as bulk delivery. However,
during TESI, the catheter is inside the patient for up to an hour, and the hydrogel–cell
mixture is exposed to body temperature through this catheter in the minutes leading to
injection. This makes the use of hydrogels with temperature-dependent cross-linking
difficult. In addition, TESI currently occurs through a single barrel, which is a challenge for
quickly cross-linking hydrogels [37].
Besides delivery methods, optimal hydrogel design may differ between diseases. As
mentioned above, hydrogels have been developed for in-situ cross-linking due to higher
calcium levels in AMI. However, for both CIHF and NIDCM, the amount of myocardial
apoptosis and, therefore, release of calcium is lower compared to AMI. This means that hy-
drogels designed for calcium-dependent in-situ cross-linking may be limited to application
in AMI [38].
3.3. Coronary Artery By-Pass Graft
In addition to the hypoxic and inflammatory environment in the failing heart, coro-
nary artery bypass grafting (CABG) also introduces oxidative stress when blood supply
to the ischemic myocardium is re-established [39]. This calls for additional shielding of
the applied cell therapy products, regardless of cell type. Cell-containing injectable hy-
drogels have been applied clinically during CABG, where they can be injected with great
precision during open chest surgery [8]. This makes the issues of TESI delivery obsolete.
Open-chest operations are open for other biomaterial applications such as scaffolds or
cell sheets. As mentioned earlier, non-injectable scaffolds or cell sheets are not included
in this review as these biomaterials utilize a different technology and could be discussed
in length in a separate review. Most of the patients treated with cell therapy for the above-
mentioned indications will not receive CABG. For large-scale treatment of such patients, it
is unlikely that an open-chest procedure will be the standard of care in the long term.
4. Cell Therapy Candidates and Hydrogel Requirements
The approaches to cell therapy for cardiac regeneration can generally be divided
into two categories. First, to boost endogenous repair mechanisms. Most adult stem cell
therapies including mesenchymal stromal cells (MSCs) and derived paracrine mediators
fall into this category. This may also simply be called cell therapy and assisted cell therapy if
hydrogels or other carriers are used. Second, to provide new contracting cells. Pluripotent
stem cell-derived cardiomyocytes, myoblasts, and cardiopoietic cells can be included into
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this category. The application of such an ex vivo generated construct is also called tissue
engineering. Cardiac tissue engineering approaches include ex vivo generated scaffolds
or cell sheets combined with contracting cell types or cells differentiating into contracting
cells. The term also includes the application of injectable hydrogels with these cells. Some
cell types fall into both categories, and therefore, the treatment is both cell therapy and
tissue engineering.
4.1. Mesenchymal Stromal Cells and Endothelial Progenitor Cells
For cardiac regeneration, mesenchymal stromal cells (MSCs) are the furthest in clinical
development [2]. These cells are relatively easily harvested and cultured for clinical
use [5]. The technology is more straightforward compared to more potent cell types,
such as induced pluripotent stem cells (iPSCs) or embryonic stem cells (ESCs), as well
as differentiated cell types from pluripotent cells. Due to the limited proliferation and
differentiation potential of MSCs, there are less safety issues. This has facilitated their
quick translation into clinical trials, providing a bulk of evidence for the safety of these
cells in cardiac indications [23,28].
Initially, MSCs were thought to transdifferentiate into cardiomyocytes, directly aiding
the pump function of the damaged heart [2]. However, overwhelming evidence has proven
that MSCs mainly exert their regenerative functions through paracrine interaction with
the surrounding cells. This can lead to immunomodulation, anti-apoptosis, and anti-
fibrosis [32,40]. As such, MSC-derived secretions have been tested as cell-free alternatives
to cell therapy. Results comparing the effect of MSCs and MSC-derived secretions on
cardiac function are, however, inconsistent, though pointing towards cell therapy being
superior [41]. Common for these approaches is that they initiate an endogenous wound
healing response, including angiogenesis, activation of macrophage subtypes, and homing
of circulating stromal cells [2].
Endothelial progenitor cells (EPCs) are derived from bone marrow or blood and are
thought to function much like MSCs. Like MSCs, they can be harvested and cultured with
relative ease, and they are deemed safe due to function as progenitors [2].
Since MSC and EPC therapy is thought to be mostly paracrine, the main goal of
combining this therapy with hydrogels is to provide a sustained release of the paracrine
mediators. As such, complete functional integration is not required, but porosity for
paracrine interaction is. A great strength of MSCs is their ability to adapt to the environment
and respond accordingly. This can be illustrated by their ability to be “licensed” by
exposing them to inflammatory mediators such as interferon-γ, which in turn boosts
their immunomodulatory abilities [42]. Therefore, for optimal utilization of MSC therapy,
the cells need to have environmental cues to respond to, and the hydrogels will have to be
permeable for these environmental cues.
New evidence suggests that the cardiac regenerative effect of MSC therapy occurs
through an induction of sterile inflammation [7]. The downstream effect of this sterile
inflammation could also be caused by engulfment or induced apoptosis of the MSCs by
the endogenous immune system [43]. This could explain why the therapy has a functional
effect despite low engraftment. If this physical interaction is indeed needed for optimal
therapy, the hydrogel must eventually release the encapsulated cells. Due to the high water
content and biodegradability of most applied hydrogels, the cells usually sediment from
the gel or are released as the gel slowly dissolves, allowing the physical interaction to occur
as the cells are slowly released [10,44].
4.2. Cardiopoietic Cells and Cardiomyocytes
An alternative to MSCs are cardiac progenitor cells (CPCs) and pluripotent stem cell-
derived cardiomyocytes [45]. In contrast to MSCs, CPCs and differentiated cardiomyocytes
may contribute by myocardial engraftment and subsequent contracting power. At present,
three ways of sorting CPCs have been successfully applied for patients with cardiovascular
disease: c-kit+ sorted cells, spheroid selection of cardiosphere-derived cells, and Sca1+
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sorted cells. Despite different sorting criteria, they possess almost identical transcription
profiles, suggesting that they have similar regenerative properties [46]. Recent evidence
suggests that CPCs can replenish adult injured cardiomyocytes and vascular cells through
differentiation. As is the case for MSCs, paracrine secretion is, likewise, a pivotal regen-
erative mechanism exerted by CPCs. Proteomic analysis of the CPC secretome revealed
a complex profile of both proteins, humoral factors, and molecules, which has the potential
to stimulate differentiation of endogenous stem cells and modulate angiogenic, fibrotic,
apoptotic, and immunological processes [46–48].
Differentiated cardiomyocytes can be generated from ESCs or iPSCs and constitute
another alternative for cell transplantations. The potential of differentiated cardiomyocytes
primarily relies on their ability to electromechanically couple with the viable host my-
ocardium by forming gap junctions with neighboring cells. Furthermore, they maintain
a sarcomeric phenotype in vivo and possess contractile properties, thus improving systolic
function. Despite the potential, delivery of differentiated cardiomyocytes has been shown
to halt the deterioration of systolic function but has failed to improve the already dimin-
ished systolic function. Furthermore, application of this cell type entails the same obstacles
including poor retention and engraftment. Therefore, novel cell vehicles for localized cell
delivery should be explored.
5. Current In Vivo Evidence
5.1. Clinical Studies
To date, three clinical studies have combined cell therapy and hydrogels (Table 1).
All treatments were performed during CABG. Though open-chest operations will not be
applicable for all patients as mentioned earlier, CABG is a good indication to test these
combination applications due to the low pump function of the heart and visibility of
the application area. Chachques et al. injected autologous bone marrow mononuclear cells
into the infarct of 15 patients during CABG [49]. The injection sites were sealed with two
layers of collagen I scaffolds, with the scaffold closest to the injection being embedded
with mononuclear cells. The combination treatment was deemed safe. Menasché et al.
administered human ESC-derived cardiovascular progenitor cells in a fibrin patch in six
patients during CABG [50]. The method proved safe in terms of off-target tumor formation
and arrhythmias, while three patients developed alloimmunization. Finally, He et al.
recently performed the first randomized controlled trial using cell therapy and hydrogels
on patients receiving CABG [8]. Eighteen patients were injected with allogeneic umbilical
cord-derived MSCs (UC-MSCs) embedded in a collagen hydrogel during CABG, 17 patients
were treated with UC-MSCs only during CABG, and 15 patients only received CABG.
The treatment was safe and the combination of UC-MSCs in the collagen hydrogel resulted
in significantly lower scar size percentage 12 months after the treatment compared to
the other groups. When focusing on the patients with a baseline left ventricular ejection
fraction (LVEF) below 40.0%, mean LVEF changes after 3, 6, and 12 months were 9.14%,
9.84%, and 9.35% in the UC-MSCs in collagen hydrogel, 3.38%, 3.39%, and 6.59% in the UC-
MSC group, and 4.17%, 4.40%, and 3.62% in the control group, respectively. The LVEF was
significantly increased at all follow-up time points for the UC-MSCs in collagen hydrogel,
while it was only significant at the 12 month follow-up for the UC-MSC group. He et al.
were the only study group to include a cell-only group, making this the first clinical
evidence of potential benefit of administering cell therapy in a hydrogel [8].
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Table 1. Clinical trials using hydrogel delivery of cell therapeutics.






CV progenitors Fibrin patch
Patch placed over
infarct area Open label NCT02057900
Chachques, 2007 CABG BMMNCs Collagenscaffold
Collagen scaffold to
close injection sites Open label N/A
He, 2020 CABG UC-MSC Collagenhydrogel
Injected cells/hydrogel
co-therapy RCT NCT02635464
CABG: coronary artery bypass graft; ESC: embryonic stem cell; CV: cardiovascular; BMMNC: bone marrow mononuclear cells; UC-MSCs:
umbilical cord-derived mesenchymal stromal cells; RCT: randomized controlled trial.
5.2. Preclinical Studies
Most studies comparing the in vivo effect of cells administered in saline with cells
administered in hydrogels report an improved beneficial effect in the hydrogel group
(Table 2). Furthermore, the majority of recent studies report cell therapy to have a positive
effect on LVEF and a larger effect size when administering cells in hydrogel compared
to the non-treated group [10,12,15,17,51–57]. Other studies found no benefit of cell ther-
apy alone, but only a functional effect of cells in hydrogels [10,13–16,48,58–62]. A direct
comparison between the cell-only group and the cell in hydrogel found significant func-
tional benefits of administration in the hydrogel [10,12–17,48,51–54,56,57,61–63]. A few of
the recent studies included both a cell-only control and a hydrogel-only control. For most
studies comparing the functional effect of cells-only and hydrogel-only groups with that
of the combination treatment, a synergistic effect was observed [10,16,17,52,54,56,57,63].
Few studies reported no improvement with the combination treatment compared to cells
only [11,45,64]. Findings include improved pump function measured as LVEF, fractional
shortening (FS), or perfusion. This is generally reported together with increased scar
thickness, increased vessel density, lower degree of fibrosis, and smaller infarct size. These
are the same parameters affected by cell therapy itself and seem to be an enhancement
of their known cardiac regenerative properties. For most studies, the enhanced benefit of
hydrogel delivery is observed together with enhanced retention of the cells, regardless of
cell type. Most studies reporting both retention and function find that these are directly
correlated. However, this does not always apply, and there is evidence that the properties
of the hydrogels are crucial for achieving enhanced efficacy.
Only few studies have made head-to-head comparisons between different types
of hydrogels regarding functional in vivo efficacy. Tan et al. compared the efficacy of
hESC-derived cardiomyocytes administered in either Matrigel, alginate, or hyaluronate
hydrogels in a rat model of subacute myocardial infarction (MI) [65]. They found that all
hydrogel deliveries improved LVEF, but hyaluronate increased LVEF more than Matrigel
and alginate. This suggests that some basic hydrogels are better suited for delivery of
certain cell types than others. However, hydrogel cell delivery can be applied in different
ways and through various routes, and the hydrogels can be tweaked with both peptide
integration and in terms of stiffness through the degree of cross-linking, which also affects
the outcome.
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Table 2. Preclinical studies using hydrogel delivery of cell therapeutics since 2016.
Study Indication Cell Type Hydrogel Functionalization Application Functional OutcomeCompared to Cells Only Additional Effects
Adult Stem Cells
Bai, 2019 AMI in rats Rat BADSC Cardiac ECM in PBS Bulk delivery IM Greater improvement ofLVEF than BADSCs
Improved cardiac differentiation
of BADSCs
Chen, 2020 AMI in mice Rat AT-MSC Transglutaminasecross-linked gelatin Bulk delivery IM
Only group which sig.
improved LVEF
Improved retention and reduced
fibrosis compared to ASC in PBS,
improved MTT assay, decreased
ANP and TNP mRNA
Choe, 2019 AMI in rats Human UC-MSC Alginate hydrogel Graphene oxide +/–reduction
Microencapsulation
IM No sig. improvement





in rats Rat BM-MSC PEG hydrogel Heparinated Bulk delivery IM
Only group which sig.
improved LVEF Improved retention














Bulk delivery IM No differencein improvement
No difference in thickness,
perfusion, or fibrosis
Gaffey, 2018 AMI in rats Rat EPCs Hyaluronatehydrogel
Adamantane and
β-cyclodextrin Bulk delivery IM
Only sig. LVEF








infarct size, number of vessels,
and decreased number of
apoptotic MSCs







in the hydrogel group
Gottipati,










Coating approach and no
clumping tested
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Table 2. Cont.
Study Indication Cell Type Hydrogel Functionalization Application Functional OutcomeCompared to Cells Only Additional Effects
Jamaiyar,
2017 AMI in rats Rat iVPC PLGA microbundles Bulk delivery IM
Only group with improved
LVEF at four weeks, but no
difference in improvement
at eight weeks
No difference in infarct length or
capillary-to-myocyte ratio




VEGF encapsulation Coated cellsdelivered IV
Greater improvement of
LVEF and perfusion than
BM-MSC
Increased vascular density
in peri-infarct and average area
of myocardial islands
in the infarct








density, expression of Ang-1,
and VEGF; decreased fibrosis.
Rabbani,








Smaller infarct area (SPECT) and
increased CD31 density








Bulk delivery IM Only group with sig.improved LVEF
Enhanced BM-MSC survival.
inhibited inflammation,
and alleviated pyroptosis of
vascular endothelial cells
Xu, 2017 AMI in rats Rat BM-MSC Chitosan hydrogel Bulk delivery IM Only group with sig.improved LVEF
Improved BM-MSC retention
in the myocardium






myocardial tissue islands in scar
tissue; decreased scar area




Bulk delivery IM Only group with sig.improved LVEF
Small-molecule hydrogel
BM-MSC improved retention
compared to BM-MSC alone
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Table 2. Cont.
Study Indication Cell Type Hydrogel Functionalization Application Functional OutcomeCompared to Cells Only Additional Effects
Extracellular vesicles




β-cyclodextrin Bulk delivery IM
Greater improvement
in LVEF compared to EVs
alone
Increased vessel density and
scar thickness






Bulk delivery Greater improvement ofLVEF than exosomes
Improved retention, decreased
CD68 density and TGF-b




Bulk delivery Greater improvement ofLVEF than EVs







Bhutani, 2018 I/R in atymic rats Human C-kit+ CPC PEG crosslinked withVPM
RGD or GFOGER or
RDG integration Bulk delivery
Only group with sig.
improved LVEEF was
non-adhesive RDG















LVEF with stiff version of
gel
Improved retention. decreased
scar size, and increased
proliferative cardiomyocytes
and non-cardiomyocytes;
MMP-12, IL-6, and bFGF
increased in cells in stiff gel
compared to the other gel
Tang, 2017 AMI in mice andpigs Human CSCs
Poly (NIPAM-AA)




myocardial T cell inflammation,
decreased scar size, amd
increased viable myocardium
and infarct thickness
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Table 2. Cont.
Study Indication Cell Type Hydrogel Functionalization Application Functional OutcomeCompared to Cells Only Additional Effects
Cardiomyocytes
Gerbin, 2020 AMI in atymicrats Human ESC-CM Collagen gel
Notch ligand delta 1
integraion Bulk delivery IM
Only group with sig.
improved LVEF Improved graft size










AMI: acute myocardial infarction; MI: myocardial infarction; I/R: ischemia/reperfusion; BADSC: brown adipose tissue-derived stem cells; MSC: mesenchymal stromal cell; AT: adipose tissue; BM: bone marrow;
WJ: Wharton’s jelly; PL: placental; UC: umbilical cord; iVPCs: induced vascular progenitor cells; EPCs: endothelial progenitor cells; EV: extracellular vesicles; CPC: cardiac progenitor cells; EDC: Explant derived
cardiac stem cells; CM: cardiomyocytes; iPSCs: induced pluripotent stem cells; ESCs: embryonic stem cells; LVEF: left ventricular ejection function; PEG: polyethylene glycol; PDMS: polydimethylsiloxane; IGF:
insulin-like growth factor; IM: intramyocardial; LVEF: left ventricular ejection fraction.
Gels 2021, 7, 7 12 of 22
6. Important Hydrogel Properties
6.1. Stiffness and Porosity
For cell therapy relying on the differentiation of the applied cells, the mechanical
properties of the gels are very important. Since cell fate is hugely affected by substrate stiff-
ness, a stiffness resembling that of cardiac tissue is preferred for differentiation. However,
hydrogels commonly applied in this field of research are softer than cardiac tissue [48]. This
is most likely to accommodate diffusion of nutrients, cell product secretions, and viability
of applied cells [48]. Kanda et al. found that coating explant-derived cardiac stem cells
(EDCs) with agarose and polydimethylsiloxane (PDMS) containing fibronectin and fibrino-
gen only improved the efficacy of EDC therapy in the stiffer version of the hydrogel [61].
Differentiation was not investigated, but the improvements were ascribed to differences
in secretory activity. This goes to show that even if the mechanisms of action of the cell
product are presumed to be differentiation and integration, it is important that secretion
of trophic factors is maintained. As such, enhanced improvement of cardiac function has
been obtained with increased differentiation of CPCs when the secretion was maintained,
but not when secretion was inhibited [48].
The impact of stiffness on differentiation also applies to the commonly used MSCs [66].
A general observation is that when MSCs start to commit to a certain lineage, their secretion
of trophic factors decreases [48]. Keeping the stiffness of the hydrogel from influencing
MSC differentiation is therefore key. In addition, it is known that the secretion from MSCs
depends on the environment. Therefore, investigating whether MSCs in the hydrogel
are capable of responding to environmental cues such as hypoxia, inflammatory stimuli,
or even co-cultured cells is important [44]. If a proper hydrogel is chosen, the mere
fact that the cells are elevated to 3D culture could increase their paracrine potential [44].
Thus, a first step in designing hydrogels for delivery of secretory cell types should be to
investigate in vitro if the applied hydrogels permit proper secretion, allow for cross-talk
with the environment, and do not induce unwanted differentiation.
For delivery of extracellular vesicles or secretomes, smaller pore size is required if
sustained delivery is to be achieved [56].
6.2. Functionalization
Hydrogels have been modified to both improve the activity of the delivered cells
as well as to induce myocardial regeneration themselves (Table 2). These properties of
hydrogels are considered complementary effects to the ones exerted by the delivered cell
product.
6.2.1. Adhesion Motifs
Bhutani et al. found that the same hydrogel encapsulation led to different out-
comes [48]. Using VPM cross-linker (GCRDVPMSMRGGDRCG) (New England Peptide)
and Maleimide-cross-linked poly(ethylene glycol) solution, they encapsulated human CPCs
and either adhesive motifs RGD or the collagen derived GFOGER peptide, or non-adhesive
RDG. While the non-adhesive hydrogel significantly enhanced the functional benefit of
CPC treatment, this was not the case for the adhesive hydrogels. The functional benefit
was correlated with the retention of the cells. Even if the GFOGER adhesive hydrogel
had similar mechanical properties as the non-adhesive hydrogel, the outcomes were still
different. The GFOGER peptide favored cardiomyocyte lineage commitment, while it
abolished the secretion of VEGF, hepatocyte growth factor, and, partially, fibroblast growth
factor. Hence, for this setup, the improved attachment and lineage commitment did not
result in a functional effect. The functional effect could not be explained purely by paracrine
secretion either, since the secretions by the cells were similar in vitro in the RGD and RDG
peptide gels.
This emphasizes that there is a complex interaction between the properties of the hy-
drogels, the incorporated motifs, and the cell product. These interactions need to be
understood in order to tailor the hydrogels to the needs of the specific cells used. This may
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be particularly important with cells such as the C-kit+ CPCs, which fall within the cell
therapy categories of both physical cardiomyocyte support and paracrine support.
6.2.2. Angiogenesis
Pro-angiogenic modifications of hydrogels have been achieved through addition of
peptides such as SDKP or SVVYGLR. The use of hydrogels with these modifications for
MSC delivery improved cardiac function to a greater extent than cells delivered alone
and increased myocardial angiogenesis in a rat model of AMI [53,54]. The SDKP modi-
fied gel itself even improved cardiac function comparable to the combined treatment of
MSCs in SDKP gel [53]. Others have achieved an enhanced angiogenic effect through
incorporation of heparin or VEGF into the hydrogel [13,59]. The MSC delivery in these
hydrogels led to improved cardiac vessel density and LVEF compared to their respective
MSC control groups, suggesting that the angiogenic effects of cell therapy can be enhanced
using modified hydrogels.
6.2.3. Graft Survival and Activity
Besides boosting angiogenesis, which has been the primary focus of hydrogel func-
tionalization, studies have tried to enhance cell survival, engraftment, and prolifera-
tion [16,48,56]. Gerbin et al. tested a hydrogel with immobilized Notch ligand Delta-1 and
hESC cardiomyocytes in an athymic rat model of AMI [16]. The combination of the Notch 1
functionalized hydrogel and hESC cardiomyocytes increased graft size and hESC cardiomy-
ocyte proliferation in vivo as well as improving cardiac function compared to controls.
Han et al. evaluated a peptide amphiphile -GHRPS NapFF hydrogel containing human
umbilical cordMSC-derived exosomes [56]. The hydrogel/exosome mixture was injected
into the MI border zone of rats, which subsequently improved LVEF compared to controls
with exosomes or hydrogel alone. Furthermore, the hydrogel improved exosome retention
and reduced cardiac inflammation and fibrosis. Choe et al. focused on protecting human
UC-MSCs from oxidative stress by microencapsulating them in graphene oxide alginate.
Further protection was generated by reducing the hydrogel. While the authors found no
significant advantage of hydrogel delivery in terms of LVEF changes compared to cells
only, the reduced graphene alginate significantly decreased the fibrosis area and increased
the thickness of the left ventricle compared to the other groups [64].
6.3. Retention is Not Everything
Most studies reporting both retention and efficacy find the retention of the adminis-
tered cells to be directly correlated with treatment effect (Table 2). Opposing this, Kanda
et al. found a less-stiff single EDC cell hydrogel encapsulation to result in increased re-
tention, but not increased functional effect, when compared to non-encapsulated EDCs.
Another formulation of the hydrogel leading to greater stiffness resulted in similarly im-
proved retention but also improved treatment effect. A comparison between the paracrine
activity of EDCs in the different gels showed that the stiffer gel increased the secretion of
IL-6 and bFGF and that both gels in general improved secretion by the cells. The point being
that even though the gel with less stiffness improved both paracrine activity and retention
of the EDCs, it was not sufficient to improve the treatment effect. The simple tuning of
stiffness, however, was able to circumvent this, but by improving cell activity instead of
retention. This underlines the necessity for increased knowledge about the mechanisms of
action of the applied cell products to properly assess the impact that the hydrogel has on
their abilities.
7. Cell Delivery Strategies
In addition to intramyocardial delivery, which has been shown to be most effective
in the clinical setting, preclinical studies have used different strategies for delivering cell-
loaded hydrogels, regarding both hydrogel encapsulation and delivery route (Figure 1).
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7.1. Bulk Delivery
The most common use of hydrogels in cell therapy has been as an injection matrix,
with administrations being performed as bulk injection (Table 2). A partially cross-linked
hydrogel is usually injected, and in-situ cross-linking or self-assembly solidifies the gel
in the myocardium and retains the cells in this new structure [30]. The bulk elivery
method can be the most straightforward approach to test since the researcher simply needs
to resuspend or mix the cell suspen i wit the hydrogel. Issues using bulk delivery
h v been addressed earlier during discussion of th different clinical indications a d
TESI cathet r. Since even partially cross-linked hydroge s tend to be mo e viscous
th n saline, the inje tions themselv s require more attention than sing saline if applied
intramyocardially. Th mor viscous fluid will require mor time to spread throughout
the myocardial fibers and can easily be ejected from the injection canal in the myocardium.
7.2. Microencapsulation
Another use of hydrogels for cell delivery is microencapsulation of a number of
cells [12]. This method can be more demanding than bulk delivery since the cell suspension
and hydrogel are often electrostatically sprayed together to form microcapsules. Another
method of encapsulation is emulsion, where the cell suspension is simply mixing cell
suspension with hydrogel and oil. This is an inexpensive method but with a low degree
of control over capsule size, which makes it unsuitable for clinical production without
extensive optimization. An increasingly popular method of overcoming the need for
electrostatic spraying is to encapsulate the cells by microfluidics [67]. This provides precise
control of microcapsule size and number of cells, even down to single-cell encapsulation.
The use of microfluidics is more feasible to implement as part of a good manufacturing
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practice (GMP) production and provides a great degree of control over the final cell–
hydrogel product. The specific microfluidic system depends on the hydrogel and cross-
linker used and has to be optimized for the cell type of interest, since factors such as nozzle
size affect cell viability and function [68]. None of the recent studies included in Table 2
used microfluidics for encapsulation. Microencapsulation has the advantage of creating
physically larger cell structures, which may result in improved retention simply due to
their size. Consequently, this makes the injected cells less prone to ejection once they are
spread in the myocardium. In addition, the microcapsules can be injected in saline and thus
do not have the same issues with viscosity as bulk delivery. Since microcapsules require
hydrogels to cross-link prior to administration, there is no limit to how the cross-linking
occurs, in contrast to bulk injection. Clinically, microencapsulation must be performed
in a sterile environment, most likely as part of the product or immediately prior to treatment.
Depending on the microencapsulation method, the prolonged time for encapsulation may
be a challenge in terms of cell viability.
7.3. Single-Cell Coating
As an alternative to microencapsulation, single cells can also be coated with the hy-
drogel. This could serve to shield the cells from the environment and the immune cells but
may not improve retention in terms of size or solidification. The mechanisms of retention
in a single-cell coating may, therefore, not be as straightforward as with bulk delivery
and microencapsulation. Gottipati et al. coated BM-MSCs with a gelatin-PEG gel and
found twice the number of transplanted cells 7 days after transplantation in a mice AMI
model [69]. Despite finding in vitro that the coating decreased macrophage engulfment
of MSCs, there was no difference in CD68 density across treatment groups in vivo. This
suggests that the improved retention was not due to improved immune evasive abilities.
Clinically, the coating approach would simply require an additional step after the pro-
duction of the cells, after which they could be delivered in saline using the optimized
treatment workflow. For cryopreserved allogeneic treatment, this either requires the coat-
ing to be freezable, or pre-treatment mixing with the freshly thawed cell product in a sterile
environment.
7.4. Delivery Route
Ghanti et al. delivered their cell products and cells in hydrogel microcapsules
in the pericardial sac. This seems to be an attractive approach in animal studies, but
this pericardial delivery method is not a part of the established clinical workflow. This
diminishes the direct large-scale translatability of the study, unless such delivery methods
are developed and implemented clinically. Liu et al. used hydrogel coating to initiate VEGF
signaling in IV-administered MSCs, increasing their homing ability and, subsequently, their
functional effect [13]. IV delivery has long been deemed inferior to both intracoronary and
TESI administration. An enhanced IV approach could truly increase the clinical workflow
and cost efficiency of cardiac cell therapy, and using hydrogels instead of genetic modifi-
cations, magnetic guidance, or target tissue modifications to boost the homing abilities of
the cells could greatly ease the translation of this technology.
8. Potential Roadblocks for Clinical Translation
Despite the impressive track record of several synthetic hydrogels, they offer a number
of disadvantages from a translational point of view [48,53–56,70]. These include possible
complicated synthesis processes that are difficult to scale up, high cost, and toxicity inside
the human body. Even with the high clinical regard of PEG and PVA, a pre-polymer
such as PEG and the cross-linkers used for preparing PVA hydrogels are expensive and
carrier systems based on them are, thus, not that easy to scale up. These roadblocks haunt
the path of synthetic hydrogels into the clinic, and some of them gradually disappear into
oblivion without ever reaching patients. For this reason, most clinically approved hydrogel
carriers are based on old concepts that have been redesigned with a new furnish. To
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satisfy the needs of the end-users while assuring high scalability, tissue engineers improve
natural and readily available biopolymers that have already been approved for clinical
applications. Especially alginate and gelatin are very promising in this regard as they are
easy to modify chemically and, thus, highly tunable for natural hydrogels. The natural
hydrogels, however, suffer from potential batch-to-batch variation and their adaptability
will always be constrained by their intrinsic properties [71,72].
In the authors’ opinion, any potential new design strategy needs to tap into these chal-
lenges one way or another to diminish the gap into the clinic. To address such challenges,
next-generation carriers have already been developed, tuning natural hydrogels to generate
self-healing, injectable, printable, and bioactive carrier systems. Numerous recent studies
have also shown that the inclusion of multifunctional 2D nanomaterials can make them
electrically active, mechanically tough, and capable of controlled drug release [73,74]. One
of the reasons that the above-mentioned next-generation carrier systems have not reached
the clinic yet is likely due to insufficient interactions between engineers and physicians. It
is easy to design and engineer something in the laboratory, but without proper consultation
with physicians and the end-user, it is highly unlikely that they ever will see the light of
day in a broader and more societal context.
8.1. Start with the End in Mind
The first thing an experienced clinician will ask when faced with new technology,
such as a hydrogel, is whether it is clinically feasible to implement. It is often not. One
of the fundamental issues with translational research is the lack of interaction between
clinicians and basic researchers or engineers. Basic researchers and engineers aim to
create the best possible hydrogel, with stiffness and motifs optimized for maximizing
therapeutic effect, but they are often not aware of the clinical reality. For the hydrogel to be
implemented in clinical settings, all aspects of the manufacturing for clinical use together
with the logistics surrounding the treatment itself must be considered. In this case, it could
be an advantage to start the design with the treatment. Since hydrogels, in our case, are for
the delivery of existing cell technology, it is important to know which cell type is used, for
which indication, and by which delivery system (Figure 2).
8.2. Treatment Scalability and Logistics
The use of freshly made hydrogel is a logistical challenge. If the hydrogel is to be
produced freshly before treatment, the facility in which the treatment is being performed
must have clean rooms and equipment to accommodate this. In line with this approach,
a core facility could produce the hydrogel for several sites, which means that it must be
stable through long-distance transportation.
Most of the studies in Table 2 applied hydrogels as bulk delivery systems for freshly
cultured cells. However, a paradigm shift has occurred in the field of cell therapy, with
the development from fresh autologous treatment towards cryopreserved allogeneic cell
products. This affects the usability of the hydrogels. For hydrogels to be incorporated
in this new clinical workflow of simply thawing the cell product prior to administration,
the hydrogel must either be freezable or mixed with the cell product before administration.
The last option will add extra handling of the therapeutic and requires a suited clean
room and additional personnel. The issue with cryopreservation of cells in a hydrogel
is that it consists of water. The crystallization during freezing will damage the cells,
and incorporation of DMSO as a cryopreservative will most likely make the hydrogel fail to
cross-link properly. This issue may be different for microencapsulated cells or coated cells.
Here, the capsules or coated cells could be frozen in a regular cryopreservation medium
and thawed when needed clinically. If hydrogels are to be used as cell delivery vehicles,
these challenges must be addressed.
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8.3. Design and Production
When deciding which type of hydrogel to develop, the hydrogel must be able to be
sterilized, produced in a sterile environment, and manufactured on a large scale according
to current GMP guidelines. Several hydrogels will not handle sterilization processes such
as gamma irradiation, auto-cleaving, and alcohol treatment while maintaining their useful
properties. This is intimately related to the fact that most polymers are highly temperature-
sensitive and some of them even undergo unwanted chemical alterations after alcohol
treatment or gamma irradiation. A potential method to remedy the challenges is via
supercritical CO2 sterilization, a procedure done typically at very low temperatures to
avoid possible thermal degradation issues [75]. In brief, supercritical CO2 sterilization is
intimately linked to a critical temperature (31.1 ◦C) and pressure (74 atm) region that gives
CO2 sufficient diffusivity to penetrate biomaterials completely in order to reach and inactive
all possible pathogens. The fact that the procedure only relies on CO2 in combination with
gentle temperature and pressure conditions makes it highly unlikely that biomaterials will
display unwanted properties because of the sterilization process.
The polymers used for the hydrogel will need to be of utmost purity and with solid
quality documentation and batch control. An example of such quality starting material
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is PRONOVA UP alginate, which has been used clinically as mono-treatment for AMI
in the form of the IK-5001 hydrogel by Ikaria [38]. The amount of documentation and
rigorous quality control is the same for all components added to the hydrogel. Over half
of the hydrogels included in Table 2 have added sequences for promoting attachment,
survival, or function. This makes the continuous production of these hydrogels that much
more vulnerable, since the companies supplying the sequences should maintain their
documentation. In addition to this, the use of some of the incorporated sequences is
patented, as is the case of RGD in patent EP1894945A2, rendering the chance of successful
clinical translation into practice very uncertain.
9. Limitations
This review has some limitations. Most of the studies investigating new therapy in car-
diac indications are in AMI. The preclinical induction of AMI is not directly translatable
to the clinical disease since the treatment is usually administered almost simultaneously
with the onset of the AMI. Therefore, the tissue is not as soft, and intramyocardial injection
is therefore feasible. This review, as all others, are potentially biased due to the general
bias in the scientific literature towards positive results. Finally, for the current review, we
only performed our search in PubMed, and with the following search string: ((hydrogel
OR scaffold OR biomaterial) AND (“cell therapy” OR “stem cell” OR “stem cells”)) AND
(cardiac OR heart). Due to the focus on stem cells in the search terms, we may not have
included all relevant studies using cardiomyocytes and hydrogels.
10. Perspectives
We have a come a long way in recent years in terms of developing hydrogel carriers for
cell therapy. Indeed, some of the carriers have already made it into clinics with promising
outcomes. Most of the applied gels have shielded the cells during the injection phase
and retain them inside the target site while offering them immune protection. However,
in the authors’ opinion, the field has not unleashed its full potential yet. Firstly, many of
the tested systems are based either on alginate, hyaluronic acid, or PEG and, therefore, are
not very bioactive. Those based on bioactive collagen and gelatin tend to degrade fast from
enzymatic degradation by collagenase. A way to address this in a scalable manner is, in our
opinion, by incorporating gelatin into either alginate- or hyaluronic acid-based hydrogels—
both of which already have been approved by the FDA—since gelatin is one of the most
bioactive polymers in the field due to its naturally abundant RGD moieties. Recent in vitro
studies have also shown that the inclusion of gelatin in polysaccharide-based hydrogels
can increase the degradation time substantially.
If the end goal of cell and hydrogel combination therapy is complete tissue integration
and continuous interaction, the formerly applied hydrogels fail by design. Conventional
hydrogels are typically made from irreversible bonds which break permanently in response
to cell spreading and migration, and for this reason, they are not able to withstand migration
from the outside for long before breaking into pieces and dissipating inside the body.
Adaptable hydrogels made from self-healable bonds could potentially yield more stable
constructs in this sense, as self-healable bonds per definition are reversible and capable
of reconnecting indefinitely [76]. This could be suitable for permanent cardiomyocyte
integration.
Many engineers are trying to develop a cell-free cardiac hydrogel therapy. Firoozi et al.
already have a strong candidate [53]. This is a next logical step in hydrogel application.
However, it may be that even with a great hydrogel construct, the optimal therapy is
still the combination of hydrogel and cell therapy as in most cases, there seems to be
a synergistic effect [16,17,52,54,56,63].
In summary, cardiac cell therapy has great potential, and this potential can be amplified
using hydrogels for delivery and shielding. Hydrogels can be tuned in many ways, but
for cell therapy, the tuning must always serve to enhance the cell product. Regardless of
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the type and attributes of the upcoming hydrogels for cardiac cell delivery, it is our hope
that the design process will begin with sparring between the engineers and the physicians.
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